Still Looking For The Off-The-Shelf Breakthrough, Allogene Touts Myeloma CAR-T Candidate

Raises Hopes Of Challenging Abecma And Carvykti

 
• By Andrew McConaghie

While a cloud hangs over the future of its CD19-targeting allogeneic candidate, Allogene points to preclinical potential of superior efficacy for ALLO-715.

Allogene building
Allogene's CD19-targeting off-the-shelf CAR-Ts have hit setbacks, putting pressure on its multiple myeloma targeting candidates to succeed. • Source: Alamy

More from Anticancer

More from Therapy Areas